Cytokinetics (CYTK) Competitors

Cytokinetics (NASDAQ:CYTK) and Intra-Cellular Therapies (NASDAQ:ITCI) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, community ranking, risk, institutional ownership, valuation, media sentiment, dividends, analyst recommendations and earnings.

Which has better earnings and valuation, CYTK or ITCI?

Intra-Cellular Therapies has higher revenue and earnings than Cytokinetics. Intra-Cellular Therapies is trading at a lower price-to-earnings ratio than Cytokinetics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cytokinetics	$19.22M	202.96	-$526.24M	-$5.29	-6.17
Intra-Cellular Therapies	$680.50M	20.64	-$139.67M	-$0.73	-180.64

Does the media favor CYTK or ITCI?

In the previous week, Cytokinetics had 24 more articles in the media than Intra-Cellular Therapies. MarketBeat recorded 27 mentions for Cytokinetics and 3 mentions for Intra-Cellular Therapies. Cytokinetics' average media sentiment score of 0.75 beat Intra-Cellular Therapies' score of 0.25 indicating that Cytokinetics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cytokinetics	13 Very Positive mention(s)	1 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Intra-Cellular Therapies	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Which has more volatility and risk, CYTK or ITCI?

Cytokinetics has a beta of 0.81, suggesting that its stock price is 19% less volatile than the S&P 500. Comparatively, Intra-Cellular Therapies has a beta of 0.69, suggesting that its stock price is 31% less volatile than the S&P 500.

Does the MarketBeat Community favor CYTK or ITCI?

Cytokinetics received 307 more outperform votes than Intra-Cellular Therapies when rated by MarketBeat users. Likewise, 79.94% of users gave Cytokinetics an outperform vote while only 65.74% of users gave Intra-Cellular Therapies an outperform vote.

Company	Underperform	Outperform
Cytokinetics	Outperform Votes 829 79.94%	Underperform Votes 208 20.06%
Intra-Cellular Therapies	Outperform Votes 522 65.74%	Underperform Votes 272 34.26%

Do analysts rate CYTK or ITCI?

Cytokinetics presently has a consensus price target of $74.44, suggesting a potential upside of 127.92%. Intra-Cellular Therapies has a consensus price target of $109.70, suggesting a potential downside of 16.81%. Given Cytokinetics' stronger consensus rating and higher probable upside, equities analysts plainly believe Cytokinetics is more favorable than Intra-Cellular Therapies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cytokinetics	0 Sell rating(s)	3 Hold rating(s)	13 Buy rating(s)	2 Strong Buy rating(s)	2.94
Intra-Cellular Therapies	0 Sell rating(s)	10 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.17

Do insiders & institutionals believe in CYTK or ITCI?

92.3% of Intra-Cellular Therapies shares are held by institutional investors. 2.7% of Cytokinetics shares are held by company insiders. Comparatively, 2.6% of Intra-Cellular Therapies shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Is CYTK or ITCI more profitable?

Intra-Cellular Therapies has a net margin of -14.07% compared to Cytokinetics' net margin of -17,906.25%. Cytokinetics' return on equity of 0.00% beat Intra-Cellular Therapies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cytokinetics	-17,906.25%	N/A	-50.21%
Intra-Cellular Therapies	-14.07%	-9.93%	-8.38%

Summary

Cytokinetics beats Intra-Cellular Therapies on 13 of the 19 factors compared between the two stocks.